Lineage Cell Therapeutics receives grant to fund novel bio-retinal patch
Lineage Cell Therapeutics was awarded a grant worth more than $500,000 for the development of a bio-retinal patch for the treatment of retinal diseases, according to a press release.
The grant was awarded by the Israel Innovation Authority and is worth up to 1.95 million Israeli new shekels, or roughly $573,000. The patch is being developed by Cell Cure Neurosciences, a subsidiary of Lineage Cell Therapeutics, in partnership with Precise Bio.
“The clinical data we are generating from our OpRegen program is increasing our confidence in the use of cell transplants to treat serious retinal conditions such as dry AMD,” Brian M. Culley, CEO of Lineage Cell Therapeutics, said in the release. “OpRegen is a suspension of RPE cells, but in certain patients with dry AMD or other degenerative conditions, there may be a role for a scaffold with single or multiple layers of cells of different or identical types.”